Hoyt Catherine R, Varughese Taniya E, Erickson Jeni, Haffner Natalie, Luo Lingzi, L'Hotta Allison J, Yeager Lauren, King Allison A
Program in Occupational Therapy, Washington University School of Medicine, St. Louis, MO, USA.
Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
Dev Med Child Neurol. 2022 Feb;64(2):168-175. doi: 10.1111/dmcn.15048. Epub 2021 Sep 17.
To summarize developmental delay among infants and toddlers with sickle cell disease (SCD).
This systematic review included studies that reported developmental outcomes of children with SCD between 0 months and 48 months of age and followed standards set forth by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
Ten studies were included, describing 596 unique developmental assessments. The rate of developmental delay ranged from 17.5% to 50% and increased with age. Cognition was the only domain included in all studies and the most frequently identified delay. One study reported that more severe SCD genotypes predicted worse development, while five studies reported no difference in rates of developmental delay across genotypes.
These findings emphasize the need for standardized screening to identify children with SCD at risk of delay at a young age to facilitate appropriate referrals for therapeutic intervention. Frequent and comprehensive developmental screening is necessary among all SCD genotypes.
总结镰状细胞病（SCD）婴幼儿的发育迟缓情况。
本系统评价纳入了报告0至48月龄SCD患儿发育结局的研究，并遵循系统评价与Meta分析的首选报告项目（PRISMA）指南所规定的标准。
纳入10项研究，描述了596次独特的发育评估。发育迟缓率在17.5%至50%之间，且随年龄增长而增加。认知是所有研究中都包含的唯一领域，也是最常发现存在延迟的领域。一项研究报告称，更严重的SCD基因型预示着发育更差，而五项研究报告不同基因型的发育迟缓率没有差异。
这些发现强调了需要进行标准化筛查，以识别幼年时有发育迟缓风险的SCD患儿，以便为治疗干预进行适当转诊。对所有SCD基因型患儿进行频繁且全面的发育筛查是必要的。
